🔎 Trials Near Me

Avaleht › Äge müeloidne leukeemia › Vermont

Äge müeloidne leukeemia kliinilised uuringud osariigis Vermont

7 uuringut haiguse Äge müeloidne leukeemia jaoks otsivad osalejaid osariigis Vermont.

Linnad osariigis Vermont

Ametlik uuringutekst (inglise keeles)

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • University of Vermont Medical Center, Burlington
  • University of Vermont and State Agricultural College, Burlington
VärbamineFaas 2
Vanused 18–59 · Kõik sood · Uuendatud 28. sept 2026 · NCT05554393

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • University of Vermont Medical Center, Burlington
  • University of Vermont and State Agricultural College, Burlington
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • University of Vermont Medical Center, Burlington
  • University of Vermont and State Agricultural College, Burlington
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT06317649

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • University of Vermont Medical Center, Burlington
  • University of Vermont and State Agricultural College, Burlington
VärbamineFaas 2
Vanused 18–59 · Kõik sood · Uuendatud 22. sept 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • University of Vermont and State Agricultural College, Burlington
VärbamineFaas 3
6 Months – 21 Years · Kõik sood · Uuendatud 17. sept 2026 · NCT04293562

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of Vermont Medical Center, Burlington
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 20. aug 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • University of Vermont, Burlington
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 20. aug 2026 · NCT06001788

Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.